ImmunoVec is developing gene therapy treatments for life-threatening hematopoietic diseases.


There are over 300 life-threatening primary immune deficiencies for which there are limited treatment options currently available.


ImmunoVec has developed a platform for the generation of lentiviral vectors that are specifically engineered for each disease target. We are able to modify the patient’s own blood stem cells and introduce a highly regulated, functional copy of the gene of interest. These gene-modified blood stem cells have the ability to give rise to a fully functional immune system, without the risk of graft-versus-host disease.


  • Endogenous expression of therapeutic gene
  • Optimal gene transfer
  • Novel genetic elements

Development Stage:

  • Pre-Clinical

Patents Issued:

  • Coming Soon

Select Publications:

  • Coming Soon